Profil
Daniela Carmen Oniciu is the founder of Creative Pharma Advisors LLC.
She worked as an Associate Director-Chemistry at Pfizer Inc. from 2004 to 2008.
Prior to that, she was a Senior Director-Chemical Research & Development at Esperion Therapeutics, Inc. from 2001 to 2004.
From 2005 to 2014, she held the position of Senior Director-Chemistry at ABIONYX Pharma SA. Later, she served as the Vice President-Preclinical Research & Development at Gemphire Therapeutics, Inc. from 2014 to 2018.
In addition to her former jobs, she also worked as the Chief Operating Officer at BioSavita, Inc. and as the Head-Research & Development at Ocuphire Pharma, Inc. Dr. Oniciu obtained her graduate and doctorate degrees from Politehnica University of Bucharest.
Ehemalige bekannte Positionen von Daniela Oniciu
Unternehmen | Position | Ende |
---|---|---|
OCUPHIRE PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2023 |
NEUROBO PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2018 |
ABIONYX PHARMA | Corporate Officer/Principal | 01.02.2014 |
PFIZER, INC. | Corporate Officer/Principal | 01.02.2008 |
ESPERION THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2004 |
Ausbildung von Daniela Oniciu
Politehnica University of Bucharest | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ABIONYX PHARMA | Health Technology |
ESPERION THERAPEUTICS, INC. | Health Technology |
PFIZER, INC. | Health Technology |
OCUPHIRE PHARMA, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
BioSavita, Inc.
BioSavita, Inc. BiotechnologyHealth Technology BioSavita, Inc. operates as a biotechnology company, which develops a technology solution for the development of therapeutic antibodies. It focuses on developing a technology platform based on yeast (saccharomyces cerevisiae) expression systems that accelerate the discovery and development of antibody therapeutics and recombinant proteins. The company was founded by Nalini Ghag-Motwani in 1993 and is headquartered in Plymouth, MI. | Health Technology |
Gemphire Therapeutics, Inc.
Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
Creative Pharma Advisors LLC |